Research and Development

Pfizer has announced the selection of its preferred once-daily modified release formulation for danuglipron, with a plan to conduct dose …

Personalised medicine technology company Spesana and Imidex, developer of computer-aided detection technology, have announced a strategic partnership to research AI’s …

iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, roginolisib.

Oxolife has announced positive phase 2 clinical data on its fertility pill OXO-001 at the European Society of Human Reproduction …

Arcturus Therapeutics has announced mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, …

NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study which assessed PrimeC …

Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for the treatment of patients with …

AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for sipavibart under the …

Precision medicine oncology company IDEAYA Biosciences has announced that the first patient in the IDEAYA-sponsored phase 1 trial has been …

The US Food and Drug Administration (FDA) has granted an expanded Orphan Drug Designation (ODD) for brain cancer immunotherapy SurVaxM, …

Abcuro has announced that it has completed the enrolment for its registrational phase 2/3 MUSCLE clinical trial, which aims to …

Asklepios BioPharmaceutical (AskBio), a subsidiary of Bayer, has announced that it has initiated the recruitment for its phase 2 REGENERATE-PD …

ILiAD Biotechnologies has announced that it has selected Emmes Group to conduct the upcoming phase 3 trials of its lead …

Vertex Pharmaceuticals has announced new data from its phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated …

Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE 1 trial, which assessed the …